1. Home
  2. CALC vs FEAM Comparison

CALC vs FEAM Comparison

Compare CALC & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • FEAM
  • Stock Information
  • Founded
  • CALC 2011
  • FEAM 2016
  • Country
  • CALC United States
  • FEAM United States
  • Employees
  • CALC N/A
  • FEAM N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • FEAM Major Chemicals
  • Sector
  • CALC Health Care
  • FEAM Industrials
  • Exchange
  • CALC Nasdaq
  • FEAM Nasdaq
  • Market Cap
  • CALC 22.9M
  • FEAM 71.5M
  • IPO Year
  • CALC N/A
  • FEAM N/A
  • Fundamental
  • Price
  • CALC $1.61
  • FEAM $3.68
  • Analyst Decision
  • CALC Strong Buy
  • FEAM Strong Buy
  • Analyst Count
  • CALC 3
  • FEAM 2
  • Target Price
  • CALC $16.33
  • FEAM $121.00
  • AVG Volume (30 Days)
  • CALC 30.2K
  • FEAM 14.0K
  • Earning Date
  • CALC 08-11-2025
  • FEAM 09-03-2025
  • Dividend Yield
  • CALC N/A
  • FEAM N/A
  • EPS Growth
  • CALC N/A
  • FEAM N/A
  • EPS
  • CALC N/A
  • FEAM N/A
  • Revenue
  • CALC N/A
  • FEAM N/A
  • Revenue This Year
  • CALC N/A
  • FEAM N/A
  • Revenue Next Year
  • CALC N/A
  • FEAM N/A
  • P/E Ratio
  • CALC N/A
  • FEAM N/A
  • Revenue Growth
  • CALC N/A
  • FEAM N/A
  • 52 Week Low
  • CALC $1.42
  • FEAM $2.82
  • 52 Week High
  • CALC $5.97
  • FEAM $29.67
  • Technical
  • Relative Strength Index (RSI)
  • CALC 47.03
  • FEAM 43.86
  • Support Level
  • CALC $1.42
  • FEAM $3.41
  • Resistance Level
  • CALC $1.85
  • FEAM $3.82
  • Average True Range (ATR)
  • CALC 0.15
  • FEAM 0.26
  • MACD
  • CALC -0.00
  • FEAM -0.00
  • Stochastic Oscillator
  • CALC 44.19
  • FEAM 47.97

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

Share on Social Networks: